Aldeyra Therapeutics to Present Phase 2b Dry Eye Disease Results at ARVO

Source: Aldeyra Therapeutics

Aldeyra Therapeutics announced that John Sheppard, MD, Professor of Ophthalmology at Eastern Virginia Medical School, will present results of the phase 2b clinical trial of topical reproxalap in dry eye disease at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting held April 28 through May 2, 2019, in Vancouver, Canada. 

Reproxalap is a novel immune-modulating RASP (Reactive Aldehyde Species) inhibitor in late-stage development for the treatment of dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson Syndrome.

Results from a phase 2b clinical trial completed in 2018 demonstrated that reproxalap was statistically superior to vehicle across multiple dry eye disease symptoms and signs. The RENEW adaptive phase 3 clinical trial of topical ocular reproxalap for the treatment of dry eye disease initiated on April 1, 2019.

Details of Aldeyra’s presentation at ARVO are as follows:

Abstract Title:  Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled Phase 2b Dry Eye Disease Clinical Trial to Evaluate Safety and Efficacy of Topical Ocular Reproxalap, a Novel RASP Inhibitor

Session Title:  Dry eye clinical

Session Number: 477

Session Date and Time:  May 1, 2019 from 3:00 PM4:45 PM

Presentation Number: 5206

Presentation Date and Time: May 1, 2019 from 4:00 PM4:15PM

Location:  Vancouver Convention Center Room West 211

Abstracts and full session details can be found at www.arvo.org.

Related Content